Senores Pharma appoints Jignesh Desai as President - Finance

Written by Ruchika Sharma Published On 2025-06-23T14:58:53+05:30 | Updated On 23 Jun 2025 3:06 PM IST

Senores Pharma appoints Jignesh Desai as President - Finance

Ahmedabad: Senores Pharma has appointed Jignesh Desai as the President - Finance.

"We’re excited to welcome Mr. Jignesh Desai as the President – Finance at Senores Pharmaceuticals," Senores informed in a Linkedin post.

With almost 30 years of experience across leading pharma and manufacturing companies, Desai brings deep expertise in corporate finance, budgeting, internal audits, cost control and regulatory compliance.

A qualified Cost & Management Accountant and ICAI member, he will play a key role in driving financial strategy and operational efficiency at Senores.

Prior to Senores, Desai held various leadership positions at Cadila Pharma, including AVP – Finance and President – Purchase. His career also includes key roles at Zydus Cadila and Gokul Refoils & Solvents Ltd.

Read also: Senores Pharma boosts heart health portfolio with acquisition of USFDA approved Enalapril Tablets ANDA from Wockhardt

Senores Pharmaceuticals Limited is a global, research-driven pharmaceutical company engaged in developing and manufacturing a wide range of pharmaceutical products predominantly for the US, Canada, and other regulated and emerging markets across various therapeutic areas and dosage forms. The companies’ current portfolio includes 61 ANDA and 22 CMO/CDMO commercial products that are permitted for distribution in the USA. Senores is also engaged in the development and manufacturing of complex generics certified by global food and drugs authorities and delivers generic drugs for emerging markets, catering to more than 40 countries. The company currently has approval from regulatory bodies of more than 10 countries for its manufacturing facility in Chhatral for emerging markets with over 280 product registrations and 630 product applications. Senores also manufactures critical care injectables and Active Pharmaceutical Ingredients (“API”). Senores has 2 manufacturing facilities for formulations – one in Atlanta, US which is USFDA approved and DEA, TAA & BAA compliant for controlled substances and government supplies & other is in Chhatral, Ahmedabad, India approved by WHO-GMP to cater to emerging markets. The company also has 2 manufacturing facilities for API in India, both located around Ahmedabad, with one in Chhatral and the other in Naroda.

senores pharmasenores pharma newsappointmentcadila pharmazydus cadila

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751